Amgen (AMGN) News Today

Amgen Inc. (NASDAQ: AMGN) shares have gyrated after the company rolled out its new direct-to-consumer strategy for key therapies. Following a near 1.3% slide on October 6, the stock regained ground on October 7 as investors digested the broader implications of these programs for patient access and company growth.

• Positive Sentiment: Amgen launched AmgenNow, its direct-to-consumer platform, offering the cholesterol drug Repatha at a nearly 60% discount to U.S. patients—expanding affordability and potentially broadening market share. Amgen to sell cholesterol drug at 60% discount direct to US consumers
• Positive Sentiment: Joining peers under political pressure, Amgen now sells select therapies directly to consumers—a move that may lower distribution costs and enhance patient engagement. Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
• Neutral Sentiment: The CNBC report also highlights Dr. Oz’s commentary on GLP-1 obesity treatments, an adjacent sector that could influence investor focus on Amgen’s future pipeline developments. Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
• Negative Sentiment: Despite these strategic moves, Amgen stock fell about 1.27% on October 6, underperforming broader market gains as investors weighed margin pressures from the steep drug‐price discount. Amgen (AMGN) Stock Sinks As Market Gains: Here's Why